PTGXPROTAGONIST THERAPEUTICS, INC.Mid cap · $8.35B · FY ending 2025-12-31
$129.89-1.16% · 2026-07-13 · EOD
30/100 composite
A transparent blend of the four reads below — each opens into the tool it comes from. Not advice.Quality0
margins & F-ScoreValue33
valuation vs its own rangeMomentum86
golden · price above 200-daySmart Money0
selling · 0 funds · 0P/16S insidersBullish stackGolden crossAbove 200-day
vs S&P 500+53.3%
6-mo excess Trailing performance1M +22.8%
3M +31.4%
6M +62.0%
YTD +49.0%
1Y +145.9%
ROIC = NOPAT ÷ (debt + equity − cash), using an effective tax rate of ~21%. Annual figures from SEC XBRL.
Net selling0P / 16S insiders · 0 funds hold · 0 Congress buys
Recent insidersWaddill William D. · DirectorSELL$1.1M
Waddill William D. · DirectorSELL$969,120
Waddill William D. · DirectorSELL$896,760
PATEL DINESH V PH D · President and CEOSELL$7.5M
Ahealth · 88/100
Self-fundingSelf-funding — generates cash
- ●One-sided insider selling 16 insider sales and no open-market buys in the recent window.
Educational tools — not financial advice. Fundamentals from SEC EDGAR (XBRL); prices are end-of-day (Databento). Scores are a transparent blend of the components shown, computed on our own data — a research aid, not a recommendation.